DURHAM, NC, UNITED STATES, March 5, 2025 /EINPresswire.com/ -- Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today that Shaperon will commence the ...
LGT Fund Management Co Ltd. acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and ...
HC Wainwright reissued their buy rating on shares of United Therapeutics (NASDAQ:UTHR – Free Report) in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $ ...
United Therapeutics stock opened at $319.96 on Thursday. United Therapeutics has a 12-month low of $221.53 and a 12-month high of $417.82. The company has a market capitalization of $14.28 billion ...
Leerink analyst Roanna Ruiz lowered the firm’s price target on United Therapeutics (UTHR) to $420 from $430 and keeps an Outperform rating on the shares. United Therapeutics’ Q4 earnings ...
United Therapeutics Corporation beats earnings expectations. Reported EPS is $6.19, expectations were $6.1. Operator: Good morning, and welcome to the United Therapeutics Corporation Fourth ...
United Therapeutics (NASDAQ:UTHR) Corporation reported its fourth-quarter 2024 earnings, revealing a notable miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of ...
Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results